CA3061270C - Bladder instillation composition containing chondroitin sulfate (20 mg/ml), hyaluronic acid (16 mg/ml), and a phosphate buffer (ph 6.1 to 7.9) with increased storage stability for treating cystitis - Google Patents
Bladder instillation composition containing chondroitin sulfate (20 mg/ml), hyaluronic acid (16 mg/ml), and a phosphate buffer (ph 6.1 to 7.9) with increased storage stability for treating cystitis Download PDFInfo
- Publication number
- CA3061270C CA3061270C CA3061270A CA3061270A CA3061270C CA 3061270 C CA3061270 C CA 3061270C CA 3061270 A CA3061270 A CA 3061270A CA 3061270 A CA3061270 A CA 3061270A CA 3061270 C CA3061270 C CA 3061270C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- component
- average molecular
- molecular weight
- hyaluronic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0266—Stands, holders or storage means for irrigation devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17000820 | 2017-05-12 | ||
EP17000820.5 | 2017-05-12 | ||
EP17173817.2A EP3400950B1 (de) | 2017-05-12 | 2017-05-31 | Blaseninstillationszusammensetzung enthaltend chondoitinsulfat (20 mg/ml), hyaluronsäure (16 mg/ml) und phosphatpuffer (ph 6,1 bis 7,9) mit erhöhter lagerstabiliät zur behandlung von cystitis |
EP17173817.2 | 2017-05-31 | ||
PCT/EP2018/061147 WO2018206357A1 (de) | 2017-05-12 | 2018-05-02 | Blaseninstillationszusammensetzung enthaltend chondoitinsulfat (20 mg/ml), hyaluronsäure (16 mg/ml) und phosphatpuffer (ph 6,1 bis 7,9) mit erhöhter lagerstabiliät zur behandlung von cystitis |
Publications (2)
Publication Number | Publication Date |
---|---|
CA3061270A1 CA3061270A1 (en) | 2018-11-15 |
CA3061270C true CA3061270C (en) | 2022-11-22 |
Family
ID=58709188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3061270A Active CA3061270C (en) | 2017-05-12 | 2018-05-02 | Bladder instillation composition containing chondroitin sulfate (20 mg/ml), hyaluronic acid (16 mg/ml), and a phosphate buffer (ph 6.1 to 7.9) with increased storage stability for treating cystitis |
Country Status (7)
Country | Link |
---|---|
US (1) | US11141424B2 (de) |
EP (1) | EP3400950B1 (de) |
KR (1) | KR102312643B1 (de) |
CA (1) | CA3061270C (de) |
ES (1) | ES2769059T3 (de) |
RU (1) | RU2745869C1 (de) |
WO (1) | WO2018206357A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022540702A (ja) * | 2019-07-18 | 2022-09-16 | ロバース、シャーンドル | 膀胱内注入用の医薬用及び/又は製薬用組成物、その製造及び用途 |
JP7124041B2 (ja) * | 2020-11-25 | 2022-08-23 | 株式会社朋 | ハンナ病変の指摘のためのプログラム |
US20240269167A1 (en) * | 2020-12-21 | 2024-08-15 | Biointelligent Technology Systems Slu | A mucosal re-epithelialization composition |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5880108A (en) | 1995-02-14 | 1999-03-09 | Bioniche, Inc. | Method for treating the internal urinary bladder and associated structures using hyaluronic acid |
US6083933A (en) | 1999-04-19 | 2000-07-04 | Stellar International Inc. | Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution |
US7820194B2 (en) * | 2001-12-21 | 2010-10-26 | Alcon, Inc. | Combinations of viscoelastics for use during surgery |
US20040161476A1 (en) | 2003-02-19 | 2004-08-19 | Hahn Sungtack Samuel | Cystitis treatment with high dose chondroitin sulfate |
ITMI20061030A1 (it) * | 2006-05-26 | 2007-11-27 | Altergon Sa | Nuova composizione comprendente glicosamminoglicani a viscosita' controllata e uso di tale composizione nella terapuia della cistite cronica |
DE102006060953A1 (de) * | 2006-12-12 | 2008-08-07 | Farco-Pharma Gmbh | Pharmazeutische Zubereitung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes |
US20080275015A1 (en) * | 2007-05-01 | 2008-11-06 | Potter Jeffrey A | Formulation and Method for Treating Interstitial Cystitis and Related Bladder Conditions |
ITPD20120098A1 (it) | 2012-03-30 | 2013-10-01 | Fidia Farmaceutici | "nuove formulazioni faramaceutiche contenenti condroitin solfato e derivati dell'acido ialuronico" |
RU2635466C2 (ru) * | 2012-04-08 | 2017-11-13 | Теракоат Лтд | Препараты термообратимого гидрогеля для применения при лечении нарушений уротелия |
ITMI20120896A1 (it) * | 2012-05-23 | 2013-11-24 | Bongulielmi Reto | Condroitina per uso in medicina |
CN105982912A (zh) * | 2015-03-02 | 2016-10-05 | 黄绣川 | 一种包含透明质酸钠和硫酸软骨素的药物组合物 |
-
2017
- 2017-05-31 EP EP17173817.2A patent/EP3400950B1/de active Active
- 2017-05-31 ES ES17173817T patent/ES2769059T3/es active Active
-
2018
- 2018-05-02 WO PCT/EP2018/061147 patent/WO2018206357A1/de active Application Filing
- 2018-05-02 CA CA3061270A patent/CA3061270C/en active Active
- 2018-05-02 RU RU2019140847A patent/RU2745869C1/ru active
- 2018-05-02 KR KR1020197034868A patent/KR102312643B1/ko active IP Right Grant
- 2018-05-02 US US16/612,011 patent/US11141424B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20210137968A1 (en) | 2021-05-13 |
WO2018206357A1 (de) | 2018-11-15 |
ES2769059T3 (es) | 2020-06-24 |
EP3400950B1 (de) | 2019-11-13 |
RU2745869C1 (ru) | 2021-04-02 |
CA3061270A1 (en) | 2018-11-15 |
KR102312643B1 (ko) | 2021-10-15 |
EP3400950A1 (de) | 2018-11-14 |
KR20200004833A (ko) | 2020-01-14 |
US11141424B2 (en) | 2021-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2403012C2 (ru) | Мукоадгезивные ксилоглюкансодержащие препараты, полезные в медицинских устройствах и в фармацевтических препаратах | |
WO2008071245A1 (de) | Pharmazeutische zubereitung für die behandlung entzündlicher erkrankungen des urogenitaltraktes | |
CA3061270C (en) | Bladder instillation composition containing chondroitin sulfate (20 mg/ml), hyaluronic acid (16 mg/ml), and a phosphate buffer (ph 6.1 to 7.9) with increased storage stability for treating cystitis | |
CZ288218B6 (en) | Medicament for treating cystitis in mammals | |
Tomas et al. | Sodium bicarbonate gels: a new promising strategy for the treatment of vulvovaginal candidosis | |
US11351113B2 (en) | Bladder instillation composition with increased storage stability and containing chondroitin sulfate (4.5 mg/ml), hyaluronic acid (16 mg/ml) and phosphate buffer (PH 6.1 to 7.9), for the treatment of cystitis | |
RU2309744C1 (ru) | Способ лечения послеродового эндометрита | |
CN100536855C (zh) | 一种聚维酮碘药物制剂及其制备方法 | |
BR112013029661B1 (pt) | Uso de uma macromolécula compreendendo um dendrímero para a preparação de um medicamento para o tratamento ou profilaxia de vaginose bacteriana | |
EP3415163B1 (de) | Zusammensetzung mit lokalanästhetischer wirkung und deren verwendung | |
Regu et al. | Ocular Delivery of Metformin for Sustained Release and in Vivo Efficacy | |
DE202017103288U1 (de) | Zusammensetzung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes in Form einer hochdosierten Wirkstoffkombination | |
DE202017103289U1 (de) | Zusammensetzung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes in Form einer Wirkstoffkombination | |
CA2269260C (en) | Treatment of cystitis with chondroitin sulfate | |
EP3496731B1 (de) | Zusammensetzung zur behandlung von erkrankungen der harnwege | |
EP4445904A1 (de) | Pharmazeutische zusammensetzung zur behandlung oder prävention von vulvovaginal-candidose | |
Samy et al. | Design, in vitro and in vivo evaluation of Fluconazole Bioadhesive Vaginal tablets | |
CN116251118A (zh) | 一种人工唾液、人工唾液爆珠及其制备和在口干症中的应用 | |
US20120245518A1 (en) | Pharmaceutical composition for the treatment of bladder disorders | |
CN104523575A (zh) | 一种盐酸羟苄唑眼用凝胶剂及其制备方法 | |
Aron, R. & Gordon | Pulmonary nocardiosis-case report and evaluation of current therapy | |
ZDRAVKOVIĆ et al. | ORIGINAL STUDIES ORIGINALNI NAUČNI RADOVI | |
UA69729A (en) | Method for correcting peroxidation in patients with multiple peptic ulcers of stomach and duodenum upon surgical treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20200204 |
|
EEER | Examination request |
Effective date: 20200204 |
|
EEER | Examination request |
Effective date: 20200204 |
|
EEER | Examination request |
Effective date: 20200204 |
|
EEER | Examination request |
Effective date: 20200204 |